PHARMACOKINETICS OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 ADMINISTRATION IN CANCER-PATIENTS

被引：0
作者：
CARUSO, B
GIAVARINA, D
JIRILLO, A
GIAVARINA, M
BALLI, M
机构：
[1] LEGNAGO HOSP,CLIN CHEM LAB,VERONA,ITALY
[2] LEGNAGO HOSP,DEPT RADIOTHERAPY & ONCOL,VERONA,ITALY
来源：
EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA | 1992年 / 12卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Data from a clinical trial with recombinant Interleukin (rIL-2) subcutaneousy administered are here reported. Five patients with cancer were administered with r-IL2. Serum levels were measured on serial samples by immunoenzymatic method. This method is easier than biological methods, allowing to measure rIL-2 only as antigen. Therefore, immunoenzymatic method can be on support in the comprehensive study of IL-2 farmacokynetic. rIL-2 was detectable in serum in all the patient treated, with different levels and time.
引用
收藏
页码：207 / 209
页数：3
相关论文
共 50 条
  • [21] SYSTEMIC ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 IN MICE
    CHANG, AE
    ROSENBERG, SA
    SURGICAL FORUM, 1984, 35 : 137 - 139
  • [22] INTRA-LYMPHATIC ADMINISTRATION OF INTERLEUKIN-2 (IL-2) IN CANCER-PATIENTS - A PILOT-STUDY
    PIZZA, G
    VIZA, D
    DEVINCI, C
    VICH, JM
    PASCUCHI, I
    BUSUTTI, L
    BERGAMI, T
    LYMPHOKINE RESEARCH, 1988, 7 (01): : 45 - 48
  • [23] ALTERATION OF DACARBAZINE PHARMACOKINETICS AFTER INTERLEUKIN-2 ADMINISTRATION IN MELANOMA PATIENTS
    CHABOT, GG
    FLAHERTY, LE
    VALDIVIESO, M
    BAKER, LH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (02) : 157 - 160
  • [24] RECOMBINANT INTERLEUKIN-2 BY CONTINUOUS INFUSION AND ADOPTIVE TRANSFER OF RECOMBINANT INTERLEUKIN-2 ACTIVATED CELLS IN PATIENTS WITH ADVANCED CANCER
    PACIUCCI, PA
    HOLLAND, JF
    GLIDEWELL, O
    ODCHIMAR, R
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) : 869 - 878
  • [25] AUGMENTATION OF ANTITUMOR CYTOTOXIC MECHANISMS IN CANCER-PATIENTS FOLLOWING CONTINUOUS INFUSION RECOMBINANT INTERLEUKIN-2 (RIL-2)
    PACIUCCI, PA
    KONEFAL, R
    BEKESI, G
    EFREMIDIS, A
    HOLLAND, JF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 360 - 360
  • [26] MODULATION OF MACROPHAGE RESPONSE TO INTERLEUKIN-2 IMMUNOTHERAPY BY INTERLEUKIN-3 IN CANCER-PATIENTS
    LISSONI, P
    ROVELLI, F
    BARNI, S
    ARDIZZOIA, A
    PITTALIS, S
    TISI, E
    PERLANGELI, V
    TANCINI, G
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1992, 373 (12): : 1217 - 1222
  • [27] APPEARANCE AND PHENOTYPIC CHARACTERIZATION OF CIRCULATING LEU 19+ CELLS IN CANCER-PATIENTS RECEIVING RECOMBINANT INTERLEUKIN-2
    ELLIS, TM
    CREEKMORE, SP
    MCMANNIS, JD
    BRAUN, DP
    HARRIS, JA
    FISHER, RI
    CANCER RESEARCH, 1988, 48 (22) : 6597 - 6602
  • [28] HORMONAL AND METABOLIC EFFECTS OF CHRONIC INTERLEUKIN-2 INFUSION IN CANCER-PATIENTS
    CHAMBRIER, C
    MERCATELLO, A
    TOGNET, E
    COTTETEMARD, JM
    COHEN, R
    BLAY, JY
    FAVROT, M
    PHILIP, T
    BEYLOT, M
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1990, 9 (02): : 251 - 255
  • [29] INVIVO ADMINISTRATION OF PURIFIED HUMAN INTERLEUKIN-2 TO PATIENTS WITH CANCER - DEVELOPMENT OF INTERLEUKIN-2 RECEPTOR POSITIVE CELLS AND CIRCULATING SOLUBLE INTERLEUKIN-2 RECEPTORS FOLLOWING INTERLEUKIN-2 ADMINISTRATION
    LOTZE, MT
    CUSTER, MC
    SHARROW, SO
    RUBIN, LA
    NELSON, DL
    ROSENBERG, SA
    CANCER RESEARCH, 1987, 47 (08) : 2188 - 2195
  • [30] SERUM INTERLEUKIN-2 LEVELS IN RELATION TO THE NEUROENDOCRINE STATUS IN CANCER-PATIENTS
    LISSONI, P
    TANCINI, G
    ROVELLI, F
    CATTANEO, G
    ARCHILI, C
    BARNI, S
    BRITISH JOURNAL OF CANCER, 1990, 62 (05) : 838 - 839
12345